Jamp Ondansetron · DIN 02490617 · 4 mg/5 mL · oral liquid
Limited Use, Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 215, 216, 217, 218, 454, 696 required
Write on scriptone applicable Reason for Use code, 215 or 216 or 217 or 218 or 454 or 696 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 215, 216, 217, 218, 454, 696
Reason for Use code 215
For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 216
For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 217
For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 218
For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation.
Coverage limit:
The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 454
For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 696
For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics.
Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Jamp Ondansetron · DIN 02490617
Manufacturer: Jamp Pharma Corporation; listing date 2020-06-30
Health Canada: Marketed since 2020-04-22 · brand JAMP ONDANSETRON · ATC A04AA01 ONDANSETRON · form Solution · route Oral · ingredients ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) 4 MG/5ML · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Ondansetron: Formulary list price $0.80 per unit (the source does not state the unit; exact figure $0.7952). What the ministry pays, not the patient.
Ministry pays: $0.7952 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02490617)
Source record
DIN 02490617: Jamp Ondansetron
Raw flags: sec12=Y, sec3=Y
Item: 562200025; group id 671; item number 1664; lccId 00102; manufacturer id JPC
Source form: O/L; strength: 4mg/5mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.7952; ministry $0.7952
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02490617
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98068
Interchangeable products
Apo-Ondansetron · DIN 02291967 · $0.7952
Mint-Ondansetron Solution · DIN 02524090 · $0.7952
Zofran · DIN 02229639 · not recorded
Shortage status: active shortage (reported not recorded, estimated to end December 11, 2026, last updated August 26, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02490617
Shortage record checked October 6, 2026